FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesEnvironmental Sustainability & the Supply of Medicines for Use in Clinical Trials
Topic: Supply Chain
White Paper
Free
Brexit & the future landscape for clinical trial supplies in the UK and Europe
Topics: Pharma Industry, Regulatory, Supply Chain
Position Paper
Free
Expanded Access: Past, Present and Future Improvements
Topics: Additional Concepts, Closeout, EAP, Execution, Forecasting / Planning
Position Paper
Free
